GlassScriptPhysician profile
Cheryl Wills
NPI 1609931013
$4,236.91
in general payments reported to CMS, 2019-2025
39 companies · $917 in 2025
The $917 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $993 · 2020: $613 · 2021: $189 · 2022: $187 · 2023: $548 · 2024: $789 · 2025: $917.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,255.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,254.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,229.13 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $495.56 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $332.43 | 2019-2025 | Repatha, Otezla, Otezla |
| Abbvie INC. | $247.96 | 2020-2024 | Vraylar, Qulipta, Ubrelvy |
| Astellas Pharma US INC | $191.18 | 2019-2025 | Veozah |
| Glaxosmithkline, LLC. | $151.89 | 2019-2025 | Arexvy, Shingrix |
| Takeda Pharmaceuticals U.S.A., INC. | $124.24 | 2019-2024 | Glassia, Trintellix |
| Grifols USA, LLC | $122.76 | 2019-2025 | Prolastin-C Liquid |
| Pfizer INC. | $121.30 | 2019-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $112.30 | 2024-2025 | Caplyta |
| Lilly USA, LLC | $108.33 | 2019-2025 | Mounjaro, Zepbound |
| Janssen Pharmaceuticals, INC | $85.64 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $69.24 | 2024-2025 | Rexulti |
| Exact Sciences Corporation | $66.10 | 2023-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $65.24 | 2019-2020 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cheryl Wills listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.